Daunorubicin HCl
DNA damaging agent; Autophagy modulator. Targets Multidrug resistance-associated protein 1 (MRP1), which interacts with SARS-CoV-2 Orf9c. Gordon et al. bioRxiv, Mar 23 2020, https://doi.org/10.1101/2020.03.22.002386.
- Datasheet: view or download
- Applications:Approved drug (U.S.) that could be repurposed
Biochemicals & reagents
23541-50-6
1) Laurent and Jaffrezou (2001), Signaling pathways activated by daunorubicin; Blood 98 913 2) Noel et al. (2008), Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis; J. Pharmacol. Exp. Ther., 325 1016 3) Masquelier et al. (2004), Relationship between daunorubicin concentration and apoptosis induction in leukemic cells; Biochem.Pharmacol. 67 1047 4) Han et al. (2011), Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells; PLoS One 6 e28491
563.98
-20°C (des.)
Daunorubicin is an antitumor antibiotic used in the treatment of acute myeloid leukemias (1). This compound induces DNA damage by intercalation (2), it also induces apoptosis in a variety of cell lines (3) and the inhibition of autophagy with chloroquine enhances daunorubicin-induced apoptosis in K562 cells (4). This compound is also cell permeable.